BIOMARIN'S NAGLAZYME GETS POSITIVE OPINION FROM CHMP FOR EU MARKETING APPROVAL

BioMarin Pharmaceutical Inc said it has received a positive opinion from the EU's Committee for Medicinal Products for Human Use (CHMP) recommending that the EU Commission grant marketing authorisation for Naglazyme, a therapy for Maroteaux-Lamy syndrome, a rare genetic disease. CHMP's opinion will be forwarded to the EU Commission, which is expected to make a formal decision on marketing authorization within three to four months, BioMarin said late yesterday.

ForexTV.com (http://www.forextelevision.com/FT/AFX/ShowStory.jsp?seq=3760)